-
Mashup Score: 1FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes - 10 month(s) ago
The FDA approved two medicines to improve blood sugar control in children 10 years and older with type 2 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 13Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction - 11 month(s) ago
This post hoc analysis of a randomized clinical trial evaluates the safety and efficacy of empagliflozin in patients with heart failure and preserved ejection fraction who are taking diuretics.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
In this Post Hoc Analysis of the #EMPEROR-Preserved Trial, #empagliflozin use was associated with improvement in HHF or CV ☠️, first HHF, total HHF, #eGFR slope, and KCCQ scores in patients with #HFpEF, regardless of background diuretics use or dose https://t.co/uZMrxBJpqf… https://t.co/DkvK0qajyw https://t.co/1zWV283LIs
-
-
Mashup Score: 2Empagliflozin HF benefits extend across spectrum of kidney disease - 12 month(s) ago
Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study. “In indicated patients, SGLT2 inhibitors should be used early in the disease process to modify cardiorenal risk and improve long-term outcomes,” Healio | Cardiology Today Editorial Board
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#Kidney disease does not influence the benefits of the #SGLT2 inhibitor #empagliflozin on major #HeartFailure events, even in patients at high renal risk @JavedButler1 @bswhealth @EndocrineToday @Nephronline #cardiotwitter https://t.co/xOPUOicLBN
-
-
Mashup Score: 4
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin vs placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO1cyU #T2D #youth
-
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin vs placebo & the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO1cyU #T2D #youth
-
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin versus placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
-
Mashup Score: 5
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet-
Efficacy and safety of the #SGLT2i #empagliflozin Vs placebo and the #DPP4i #linagliptin Vs placebo in young people with #T2DM (#DINAMO): a multicentre, randomized, double-blind, parallel group, phase 3 trial https://t.co/g9X0AH4jjY @TheLancetEndo #CardioTwitter https://t.co/vqJavd9Yn1
-
-
Mashup Score: 3
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Efficacy & safety of the #SGLT2 inhibitor #empagliflozin vs placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
-
Mashup Score: 0
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Online—Efficacy & safety of the #SGLT2 inhibitor #empagliflozin versus placebo & the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
-
Mashup Score: 1
Empagliflozin provided clinically relevant placebo-corrected reductions in HbA1c, whereas linagliptin did not, and might offer a new treatment option for young people with type 2 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy and safety of the #SGLT2 inhibitor #empagliflozin versus placebo and the #DPP-4 inhibitor #linagliptin versus placebo in #young #people with type 2 #diabetes (#DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial https://t.co/fdz3fO0EJm #T2D
-
#Empagliflozin approved for youth 10 years & older who have #T2D. #SGLT2i https://t.co/C0c5lQutsz